These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 27769352)

  • 1. Phospho-BRD4: transcription plasticity and drug targeting.
    Chiang CM
    Drug Discov Today Technol; 2016 Mar; 19():17-22. PubMed ID: 27769352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small-Molecule Targeting of BET Proteins in Cancer.
    French CA
    Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
    Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
    EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review.
    Yang CY; Qin C; Bai L; Wang S
    Drug Discov Today Technol; 2019 Apr; 31():43-51. PubMed ID: 31200858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.
    Picaud S; Da Costa D; Thanasopoulou A; Filippakopoulos P; Fish PV; Philpott M; Fedorov O; Brennan P; Bunnage ME; Owen DR; Bradner JE; Taniere P; O'Sullivan B; Müller S; Schwaller J; Stankovic T; Knapp S
    Cancer Res; 2013 Jun; 73(11):3336-46. PubMed ID: 23576556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma.
    Xu L; Chen Y; Mayakonda A; Koh L; Chong YK; Buckley DL; Sandanaraj E; Lim SW; Lin RY; Ke XY; Huang ML; Chen J; Sun W; Wang LZ; Goh BC; Dinh HQ; Kappei D; Winter GE; Ding LW; Ang BT; Berman BP; Bradner JE; Tang C; Koeffler HP
    Proc Natl Acad Sci U S A; 2018 May; 115(22):E5086-E5095. PubMed ID: 29764999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical trials for BET inhibitors run ahead of the science.
    Andrieu G; Belkina AC; Denis GV
    Drug Discov Today Technol; 2016 Mar; 19():45-50. PubMed ID: 27769357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting.
    Wu SY; Lee AY; Lai HT; Zhang H; Chiang CM
    Mol Cell; 2013 Mar; 49(5):843-57. PubMed ID: 23317504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoiesis provides a BRD's eye view of BET protein function.
    Stonestrom AJ; Hsu SC; Werner MT; Blobel GA
    Drug Discov Today Technol; 2016 Mar; 19():23-28. PubMed ID: 27769353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel approaches to targeting BRD4.
    Kharenko OA; Hansen HC
    Drug Discov Today Technol; 2017 Jun; 24():19-24. PubMed ID: 29233295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal induction of BRD4 phosphorylation Results in Chromatin Remodeling and BET inhibitor Resistance in Colorectal Cancer.
    Wang W; Tang YA; Xiao Q; Lee WC; Cheng B; Niu Z; Oguz G; Feng M; Lee PL; Li B; Yang ZH; Chen YF; Lan P; Wu XJ; Yu Q
    Nat Commun; 2021 Jul; 12(1):4441. PubMed ID: 34290255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
    Ramadoss M; Mahadevan V
    Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
    Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
    Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding Kinetics versus Affinities in BRD4 Inhibition.
    Kuang M; Zhou J; Wang L; Liu Z; Guo J; Wu R
    J Chem Inf Model; 2015 Sep; 55(9):1926-35. PubMed ID: 26263125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomain Drug Discovery - the Past, the Present, and the Future.
    Pervaiz M; Mishra P; Günther S
    Chem Rec; 2018 Dec; 18(12):1808-1817. PubMed ID: 30289209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.